Lexicon Pharmaceuticals Statistics
Total Valuation
LXRX has a market cap or net worth of $352.53 million. The enterprise value is $200.03 million.
Important Dates
The last earnings date was Tuesday, November 12, 2024, after market close.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
LXRX has 361.49 million shares outstanding. The number of shares has increased by 40.47% in one year.
| Current Share Class | 361.49M |
| Shares Outstanding | 361.49M |
| Shares Change (YoY) | +40.47% |
| Shares Change (QoQ) | +16.30% |
| Owned by Insiders (%) | 1.18% |
| Owned by Institutions (%) | 31.85% |
| Float | 182.14M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 54.25 |
| Forward PS | 7.17 |
| PB Ratio | 1.97 |
| P/TBV Ratio | 2.63 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 38.25 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.45, with a Debt / Equity ratio of 0.59.
| Current Ratio | 7.45 |
| Quick Ratio | 7.25 |
| Debt / Equity | 0.59 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -12.32 |
Financial Efficiency
Return on equity (ROE) is -136.09% and return on invested capital (ROIC) is -49.80%.
| Return on Equity (ROE) | -136.09% |
| Return on Assets (ROA) | -44.16% |
| Return on Capital (ROIC) | -49.80% |
| Revenue Per Employee | $18,347 |
| Profits Per Employee | -$759,274 |
| Employee Count | 285 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 149.99 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -12.93% in the last 52 weeks. The beta is 1.24, so LXRX's price volatility has been higher than the market average.
| Beta (5Y) | 1.24 |
| 52-Week Price Change | -12.93% |
| 50-Day Moving Average | 1.61 |
| 200-Day Moving Average | 1.89 |
| Relative Strength Index (RSI) | 25.79 |
| Average Volume (20 Days) | 4,301,031 |
Short Selling Information
The latest short interest is 28.65 million, so 7.93% of the outstanding shares have been sold short.
| Short Interest | 28.65M |
| Short Previous Month | 27.65M |
| Short % of Shares Out | 7.93% |
| Short % of Float | 15.73% |
| Short Ratio (days to cover) | 10.26 |
Income Statement
In the last 12 months, LXRX had revenue of $5.23 million and -$216.39 million in losses. Loss per share was -$0.74.
| Revenue | 5.23M |
| Gross Profit | -67.67M |
| Operating Income | -211.12M |
| Pretax Income | -202.11M |
| Net Income | -216.39M |
| EBITDA | -210.56M |
| EBIT | -211.12M |
| Loss Per Share | -$0.74 |
Full Income StatementBalance Sheet
The company has $258.37 million in cash and $105.87 million in debt, giving a net cash position of $152.50 million or $0.42 per share.
| Cash & Cash Equivalents | 258.37M |
| Total Debt | 105.87M |
| Net Cash | 152.50M |
| Net Cash Per Share | $0.42 |
| Equity (Book Value) | 178.51M |
| Book Value Per Share | 0.49 |
| Working Capital | 232.56M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$207.84 million and capital expenditures -$557,000, giving a free cash flow of -$208.39 million.
| Operating Cash Flow | -207.84M |
| Capital Expenditures | -557,000 |
| Free Cash Flow | -208.39M |
| FCF Per Share | -$0.58 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -4,037.43% |
| Pretax Margin | -4,138.32% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -5,387.81% |
Dividends & Yields
LXRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -40.47% |
| Shareholder Yield | -40.47% |
| Earnings Yield | -61.38% |
| FCF Yield | -59.11% |
Analyst Forecast
The average price target for LXRX is $6.00, which is 515.26% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.00 |
| Price Target Difference | 515.26% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 248.54% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on May 21, 2015. It was a reverse split with a ratio of 0.1428571:1.
| Last Split Date | May 21, 2015 |
| Split Type | Reverse |
| Split Ratio | 0.1428571:1 |
Scores
LXRX has an Altman Z-Score of -7.6 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -7.6 |
| Piotroski F-Score | 4 |